ISRCTN31004502已完成未知
A randomised, double blind, placebo controlled, crossover trial of the adjuvant properties of imipramine for the overactive bladder
The Whittington Hospital NHS Trust (UK)0 个研究点目标入组 40 人开始时间: 2008年2月20日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Age >= 18 years
- •2. Able to consent
- •3. Suffering from overactive bladder symptoms
- •4. Taking antimuscarinic treatment for detrusor overactivity
排除标准
- •1. Unable to consent
- •2. Pregnant
- •3. Breast feeding
- •4. Recent myocardial infarction
- •5. History of psychiatric illness
- •6. Taking monoamine oxidase inhibitors
- •7. <18 years
研究者
相似试验
进行中（未招募）
1 期
A randomised, double blind, placebo controlled, crossover trial of the adjuvant properties of imipramine for the overactive bladder. - RCT of adjuvant imipramine for the overactive bladderEUCTR2008-000893-19-GBWhittington NHS Trust40
进行中（未招募）
不适用
A randomised, double blind, placebo controlled, cross over study of the effects of Buprenorphine Hemiadipate Hydrochloride/Naloxone Hydrochloride Dihydrate intravenous challenges in opioid dependent subjects stabilisied on sublingual Buprenorphine Hydrochloride/Naloxone Hydrochloride Dihydrate (Suboxone)Maintenance/substitution agent for the treatment of opioid dependence.MedDRA version: 14.1Level: LLTClassification code 10012346Term: Dependence on opiatesSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2011-002229-23-GBRB Pharmaceuticals Inc.
进行中（未招募）
不适用
A randomised, double blind, placebo-controlled, cross-over pilot study to examine the safety, tolerability and pharmacodynamic profile of repeat oral doses of SLx-2101 once daily for up to 14 days in patients with secondary Raynaud’s disease.Raynaud's DiseaseMedDRA version: 8.1Level: LLTClassification code 10037917Term: RaynaudsEUCTR2007-000397-23-DESurface Logix, Inc.
进行中（未招募）
1 期
A randomised, double blind, placebo-controlled, cross-over study of the effects of dehydroepiandrosterone replacement on vascular function in patients with primary and secondary adrenal insufficiency.EUCTR2005-000115-10-GBCardiff University40
已完成
不适用
This is a single center study wherein the efficacy of Sabeet® in cardiovascular and exercise performance will be studied in 20 adult male healthy volunteers in comparison to Placebo using a crossover design.CTRI/2015/11/006387Sami labs Limited20